Ivonescimab plus chemo before surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that is considered borderline resectable (the tumor is close to important blood vessels but may still be removable).
- You have not had any previous treatment for pancreatic cancer.
- You are in generally good health (able to do daily activities with little or no help).
- Your tumor is not larger than 6 cm and has not spread to nearby lymph nodes or other organs.
- You have adequate blood cell counts, liver and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.